Press Releases
Lupus Research Alliance Announces Seven Recipients of the 2020 Lupus Innovation Award

NEW YORK, NY, November 9. The Lupus Research Alliance proudly announced today the 2020 Lupus Innovation Award recipients. These seven projects represent a wide breadth of scientific exploration in lupus, probing the development and progression of lupus while pointing to potential treatment approaches. The Lupus Innovation Award offers up to $150,000/year total costs for up […] READ MORE

LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis

September 16, 2020 NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New England Journal of Medicine, demonstrating that GSK’s drug Benlysta® (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney. The […] READ MORE

MARCH 26 STATEMENT: Lupus Research Alliance Puts Plaquenil (Hydroxychloroquine) Shortage into Perspective for Lupus Community

March 26, 2020 The Lupus Research Alliance (LRA), the world’s leading research organization dedicated to lupus research, continues to watch rapidly changing developments regarding COVID-19 and is closely monitoring the policies and actions of the federal government, healthcare agencies, medical organizations and the pharmaceutical industry on behalf of people with lupus. Thrust into the spotlight […] READ MORE

New Phase 3 Study Shows Positive Results for Benlysta® in Lupus Nephritis

December 17, 2019 The Lupus Research Alliance is thrilled to share exciting news from GSK that Benlysta (belimumab) demonstrated positive clinical trial results in treating lupus nephritis (LN), a common complication of lupus causing inflammation of the kidneys that can result in end-stage kidney disease. Called BLISS-LN, this Phase 3 trial is the largest one […] READ MORE

Lupus Research Alliance Response to Positive Data from Phase 3 Anifrolumab Trial Presented at 2019 ACR/ARP Annual Meeting

NEW YORK, NY – November 11. The Lupus Research Alliance (LRA) congratulates AstraZeneca on new positive results from the Phase 3 TULIP-2 trial (Treatment of Uncontrolled Lupus via the Interferon Pathway) presented at the 2019 ACR/ARP Annual Meeting.  The data showed that the investigational biologic treatment anifrolumab significantly reduced disease activity for people with lupus. […] READ MORE

Learn and connect with our community!